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Abstract 
 
Background: A sizeable number of recent studies investigating whether clients with substance misuse 
and mental health problems (dual diagnosis clients) are at heightened risk of dropout from drug 
treatment have been published. It is timely that their findings are brought together in a comprehensive 
review of the current evidence. 
Aims: The aim of the review is to examine whether dually diagnosed clients are less likely to be 
retained in drug treatment than clients without mental health problems, and if so, whether this varies for 
clients diagnosed with different types of mental health problems.  
Methods: The review considers peer-reviewed research published after 1 January 1990, which was 
located using the literature databases Medline and PsycInfo. Pre-defined search terms were used. 
Further papers were identified from the bibliographies of relevant publications.  
Findings: 58 studies (84% from the US) met the inclusion criteria for the review. The findings suggest 
that for most clients, having a past history of mental health problems does not influence the likelihood of 
being retained in drug treatment. The body of evidence regarding concurrent mental health problems is 
contradictory. On the whole, the majority of studies suggest that neither presence nor severity of 
depressive, anxiety, or other Axis-I disorders is related to retention, but these findings are not entirely 
unequivocal, as a few studies report strong positive or negative associations between depression and 
anxiety disorders and retention. Few researchers looked separately at psychotic spectrum disorders 
hence no conclusions could be drawn. The presence of most personality disorders also did not appear 
to affect treatment tenure, with the exception of anti-social personality disorder, for which the evidence 
points towards a greater risk of dropout.  
Conclusions: The balance of evidence suggests that overall, dual diagnosis clients with Axis-I 
disorders who seek treatment in drug treatment services are retained as well as clients without dual 
diagnosis. Subgroups of clients who appear more vulnerable to premature dropout include those with 
anti-social personality disorder. Methodological shortcomings of the reviewed studies and resulting 
implications for this review and future research are discussed.  
 
 
Keywords: Systematic review, dual diagnosis, comorbidity, mental health, dropout, retention 
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Introduction 
 
Retention in drug treatment has long been recognised as a crucial process factor determining positive 
treatment outcomes. Clients staying in treatment longer have been shown to have superior outcomes 
across the whole range of outcome domains compared to those that leave prematurely (e.g., Stark 
1992; Simpson et al. 1997; Gossop, Marsden, Stewart and Rolfe 1999; Siqueland et al. 2002; Zhang et 
al. 2003; Hser et al. 2004). Despite this, studies continue to report high dropout rates in all drug 
treatment modalities (Gossop et al. 1998; Gossop, Marsden, Stewart, Lehmann et al. 1999; Gossop, 
Marsden, Stewart and Rolfe 1999; Hser et al. 2001; Klein et al. 2002). For the past 30 or so years, huge 
research effort has gone into the identification of risk factors for early dropout. Amongst these, one risk 
factor which has received a significant amount of attention is the presence or absence of mental health 
problems.  
 
Clients accessing drug treatment may present for treatment with a number of psychological or 
psychiatric problems, and co-morbidity of psychiatric problems and substance dependence is common. 
Recent prevalence estimates of such co-morbidity in drug treatment samples were reported to range 
from 20% to 93% (Marsden et al. 2000; Franken and Hendriks 2001; Virgo et al. 2001; Manning et al. 
2002; Weaver et al. 2003).  
 
Amongst clinicians as well as researchers, there often appears to be an underlying assumption that 
clients with a psychiatric co-morbidity are more difficult to retain in drug treatment settings and major 
research effort has gone into trying to establish the relationship between “dual diagnosis” and treatment 
retention. The only literature on this topic to date is a short section in a clinically-oriented narrative 
review of a range of predictors of drug treatment retention (Stark et al 1992). Stark and colleagues 
reviewed research published prior to 1990, and it is not clear on what basis studies were located and 
selected. Thus it is timely to try to bring together the results of studies exploring the link between dual 
diagnosis and retention in drug treatment. 
 
 
METHODS 
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Inclusion criteria 
 
Inclusion criteria were (1) the treatment was delivered either in substance misuse services or, 
considered separately, specialist dual diagnosis services; (2) the authors report comparisons of 
completion rates or length of stay between clients with varying levels or diagnoses of psychological or 
mental health problems, (3) the authors report original research with samples of at least 20 clients 
(excluding reviews, clinical intervention descriptions, case studies and very small sample studies), and 
(4) the papers were published in English-language peer-reviewed journals between January 1990 and 
March 2006 (prior research is reviewed in Stark et al, 1992). Reports focusing specifically on treatment 
in general psychiatry settings, or telephone/web-based treatment were excluded because of the 
differences in client groups and service delivery. Studies were also excluded if they reported on 
variations in retention rates for different treatments for a homogenous group of dual diagnosis clients.  
 
(Insert Table 1 about here) 
 
Procedure 
 
The electronic databases Medline, PsycInfo and ISI Web of Social Science were searched for articles 
meeting the above inclusion criteria. The list of search terms used is given in Table 1. The retention 
search string was paired in turn with each of the dual diagnosis search strings. Duplicates were 
removed and abstracts for all located articles were obtained and classified as (1) definitely reporting a 
result linking mental health problems and retention, (2) potentially reporting a result linking mental 
health problems in a relevant setting (where the abstract was vague on the included list of retention 
predictors or treatment setting), (3) definitely not reporting a relevant result, (4) treatment setting in 
general psychiatry, review articles, sample <30, clinical intervention descriptions. The full-text versions 
of all articles classified as (1) or (2) were obtained and read by two independent reviewers, the first 
author and a postgraduate student, to make a final decision on eligibility for inclusion. The 
bibliographies of located articles were hand-searched for further articles.  
 
For each study, we abstracted (where available) information on the geographical region of the study, 
study design, mental health measure, retention measure, overall retention rate, retention rates by client 
subgroups, prevalence of dual diagnosis in the sample, total sample size, sample composition in terms 
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of substance type or any special characteristics, intervention/treatment type and whether the study 
explicitly aimed to find out about the link between mental health and retention or whether this was 
merely an additional finding reported by the authors.     
 
We considered undertaking a meta-analysis of the included studies to help us make sense of the 
contradictory results we report below and increase the power and precision of our conclusions. 
However, studies were clinically and methodologically heterogeneous regarding design, chosen 
predictor and outcome measures, treatment populations and settings (see the sample of studies section 
below) so that it proved impossible to define large enough homogenous subgroups of studies which 
would have lent themselves to a meta-analytic approach.  
 
RESULTS 
 
 
Sample of studies 
 
We were able to identify 58 studies that report on the relationship between mental health problems and 
retention in drug treatment, together including some 15,000 clients. In terms of geographical origin, 49 
of the 58 studies were from the USA, three from Canada, one from Australia, four from southern Europe 
and three from northern Europe.   
 
There were some commonalities in the methodological approach of all included studies: They followed 
clients entering one or more treatment service/modality, assessed psychopathology at the start of 
treatment and obtained a measure of either completion of a period of treatment or length of stay. The 
studies took one of three methodological approaches to report on the relationship between retention 
and psychological health: (1) division of the sample by diagnostic group or symptom severity and 
comparing these groups on retention measures (2) division of the sample into completers and non-
completers and comparing the groups regarding psychopathology at intake, and (3) correlation of a 
measure of length of stay with a psychopathology at intake score. Studies using group designs either 
compared clients with and without comorbidity, or clients with different diagnoses, whereas correlational 
studies measured the severity of psychiatric symptoms and length of stay as a continuous variable. The 
included studies varied widely according to sample size (ranging from 55 to 5269). 
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Type of mental health problem 
 
Depression 
 
Twenty-three studies looked at the effects of concurrent depression (see Table 2), and most found no 
relationship between presence and/or severity of depression and retention in a number of different 
treatment modalities (Ravndal and Vaglum; Ryan et al. 1995; Alterman et al. 1996; Araujo et al. 1996; 
Galanter et al. 1996; Charney et al. 1998; Siqueland et al. 1998; Avants et al. 1999; Hiller et al. 1999; 
Petry and Bickel 1999; Avants et al. 2000; Lang and Belenko 2000; Knight et al. 2001; Sayre et al. 
2002; Gonzalez et al. 2003; Meier et al. 2006). Two studies found that retention was better for 
depressed clients (Martinez-Raga et al. 2002; Gerra et al. 2006) and three others found that depression 
was related to dropout (Kleinman et al. 1992; Kokkevi et al. 1998; Curran et al. 2002). However, Curran 
et al’s study makes a useful distinction between severity of depression: whilst severe depression was 
related to treatment tenure, mild depression was not. Two papers derived from the large scale DATOS 
study (Broome et al. 1999; Joe et al. 1999) suggest an interaction of psychiatric problems with 
treatment modality: there was no effect of depression on retention in methadone maintenance or 
abstinence-oriented outpatient programmes, but in residential programmes current depression was 
related to completion. However, since none of the other studies set in residential rehabilitation services 
reported a significant effect, no clear pattern of differences between modalities can be detected. Studies 
also did not seem to differ by primary substance (ie whether samples consisted mainly of opiate, 
cocaine or alcohol users). Overall, the bulk of the evidence suggests that neither presence nor severity 
of depression influences whether a client is retained in treatment. 
 
(Insert Table 2 about here) 
 
Anxiety, attention deficit hyperactivity and posttraumatic stress disorder 
 
In comparison to depressive disorders, anxiety disorders have received somewhat less attention and 
only nine studies reporting on this were located. Those with anxiety disorder were less likely to be 
retained compared with drug use-only patients in two studies (Lang and Belenko 2000; Gerra et al. 
 7
2006) but more likely to be retained in another (Kokkevi et al. 1998). In the remaining six studies, no 
relationship was found (Araujo et al. 1996; Broome et al. 1999; Hiller et al. 1999; Knight et al. 2001; 
Martinez-Raga et al. 2002; Meier et al. 2006). Again, there were no obvious explanations for the 
contradictory findings, as studies covered all treatment modalities as well as substance use categories. 
There was only one study each specifically looking at attention deficit hyperactivity disorder (King et al. 
1999) and posttraumatic stress disorder (Martinez-Raga et al. 2002), both studies found no effect of the 
presence or absence of the disorders on retention.  
 
Psychosis  
 
Only two studies reported on the retention of those with psychotic disorders in drug treatment (see 
Table 2). In fact, in many studies, clients with acute psychotic symptoms were excluded. One study 
found no difference in retention rates (Galanter et al. 1996), however, another reported that the 
retention rate for schizophrenia clients was far lower than that of clients with depressive, anxiety or 
personality disorders (Gerra et al. 2006). Only 8% of clients with psychosis were retained in this study, 
compared to 72% of those with major depression, 18% of those with personality disorders, or 45% of 
those without a dual diagnosis. It needs to be noted that Gerra et al’s sample included only a small 
number of clients with psychotic disorders, hence results may not be reliable. In both studies, clients 
had access to regular psychiatric medication and care, however, the Galanter et al study is based in a 
highly specialised inpatient programme whereas the Gerra et al study is set in an outpatient substitute 
prescribing programme.   
 
 
Axis-I disorders 
 
Seven studies did not distinguish between different Axis-I disorders and compared clients with any Axis-
I disorder to those without mental health problems or those with Axis-II disorders only. No effect for the 
presence of Axis-I disorders on retention was reported by most studies (Greenberg et al. 1994; 
Nuttbrock et al. 1998; Siqueland et al. 1998; Maremmani et al. 2000; Cacciola et al. 2001). In contrast, 
only one study reported better retention of clients with Axis-I disorders (Saxon and Calsyn 1995) and 
one large-sample study worse retention (Moos and King 1997). Again, there is limited and contradicting 
evidence in support of a link between mental health problems and retention. 
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(Insert table 3 about here.) 
 
Personality disorders 
 
A number of studies have looked at the effect of personality disorders (PDs) on treatment retention, with 
most evidence available for clients with antisocial personality disorder (APD, see Table 3). Not all 
studies differentiated between different PDs, and three studies that compared dropout in clients with a 
diagnosis of any personality disorder versus no personality disorder reported a link between PD and 
dropout (Cacciola et al. 2001; Ball et al. 2005; Gerra et al. 2006). This effect appeared to be 
independent of whether clients also had an Axis-I disorder (Cacciola et al. 2001).  
 
Five studies reported findings that clients with a diagnosis of APD were more likely to drop out 
(Greenberg et al. 1994; Siqueland et al. 1998; Avants et al. 1999; Goldstein et al. 2001; Martinez-Raga 
et al. 2002), however, other studies were not able to replicate these findings and did not find an 
association of APD and retention (Gill et al. 1992; Alterman et al. 1996; Kokkevi et al. 1998; King et al. 
2001). One study actually found a relationship with longer retention, however, this was in a small 
sample of perinatal substance misusing women, where those with APD were retained longer than 
women without APD (Haller et al. 1997). 
 
Borderline personality disorder (BPD) was associated with an increased risk of dropout in one study 
(Martinez-Raga et al. 2002) but not in three others (Kokkevi et al. 1998; Siqueland et al. 1998; Darke et 
al. 2005).  
 
No effect was found for any of the other PDs (Greenberg et al. 1994; Marlowe et al. 1997; Kokkevi et al. 
1998; Siqueland et al. 1998).  
 
Finally, in one sample consisting of clients with personality disorder, the overall severity of symptoms 
was related to dropout (Ball et al. 2005), but in another study with 75% of the sample suffering from a 
PD the overall severity of PD symptoms was unrelated to dropout (Marlowe et al. 1997). 
 
Level of symptom severity 
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Several studies looked at overall severity of the clients’ psychological problems rather than at 
diagnoses (see Table 4). Most of these studies used either the Addiction Severity Index subscale for 
psychological/psychiatric symptoms or the Symptom Check List-90. Eight studies found that the 
severity of a client’s psychological symptoms was unrelated to retention (Epstein et al. 1994; Ryan et al. 
1995; Saxon et al. 1996; Ross et al. 1997; Tidey et al. 1998; McCaul et al. 2001; Sayre et al. 2002; 
Wallace and Weeks 2004). However, there is also a considerable amount of evidence that clients with 
more severe symptoms were more likely to leave treatment (Carroll et al. 1993; Petry and Bickel 1999; 
Lang and Belenko 2000; Haller et al. 2002; Haller and Miles 2004; Kissin et al. 2004; Van Stelle and 
Moberg 2004). Moreover, three further studies reported gender differences: two studies found that 
symptom severity was related to early drop out in women but not men (Mertens and Weisner 2000; 
Siqueland et al. 2002), but another associated severe symptoms with drop out in men only (Green et al. 
2002). Petry and Bickel (1999) stress the importance of the therapeutic alliance: Clients with a good 
client-counsellor relationship stayed regardless of symptom severity, but of those with a poor 
relationship, clients with severe symptoms were more likely to drop out than those with mild symptoms. 
This might suggest that a good alliance buffers against potentially negative effects of psychological 
problems. 
 
(Insert Table 4 about here) 
 
History of past mental health problems 
 
There were five studies that used clients’ mental health treatment histories as a proxy for psychiatric 
problems in the past. All but one of these studies found that past mental health treatment does not 
affect retention (Agosti et al. 1996; Hiller et al. 1999; Claus and Kindleberger 2002; Brady et al. 2004), 
however one reports that amongst offenders in residential rehabilitation a mental health treatment 
history was a good predictor for dropout (Lang and Belenko 2000). It has to be noted that the latter 
study investigated a large number of predictors in a relatively small sample and there may be 
methodological concerns about power and multiple testing. Two of the already mentioned studies also 
used indicators of previous rather than current mental health problems (Broome et al. 1999; Gonzalez 
et al. 2003) and largely support the notion that past problems do not affect retention, although Broome 
et al found that in methadone treatment only, lifetime diagnoses of depression and anxiety were related 
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to dropout. The majority of evidence therefore indicates that if there is a relationship between mental 
health and treatment retention, concurrent problems are more important than past problems only.  
 
Specialist treatment versus standard drug treatment 
 
Nine of the reviewed studies specified offering either specialist DD treatment or concurrent psychiatric 
treatment for dual diagnosis clients. Six were set in specialist dual diagnosis services (Greenberg et al. 
1994; Galanter et al. 1996; Ross et al. 1997; Mierlak et al. 1998; Maremmani et al. 2000; Ball et al. 
2005), two specifically mentioned facilitated access to psychiatric care (Saxon and Calsyn 1995; Brady 
et al. 2004) and one was based on dual-diagnosis focused 12-step groups (Laudet 2003). Of these 
studies, four reported no effect of various mental health indicators on retention (Greenberg et al. 1994; 
Galanter et al. 1996; Ross et al. 1997; Maremmani et al. 2000; Brady et al. 2004). One study reported a 
positive effect of Axis-I disorders (Saxon and Calsyn 1995), two a negative effect of personality 
disorders (Greenberg et al. 1994; Ball et al. 2005), one a negative (Mierlak et al. 1998) and one a 
positive effect (Laudet 2003).of prior mental health treatment on retention. The patterns of findings is 
broadly consistent with those in non-specialist services.  
 
Effects of scheduled treatment duration 
 
We investigated whether the scheduled duration of treatment is an important factor in explaining some 
of the inconsistency in the results. Detoxification programmes can be as short as one week, whereas 
methadone maintenance programmes and residential rehabilitation treatment can last between 6 
months and several years. Information on the duration of treatment can be found in the last column in 
Tables 1-4. There were more studies on long-term treatments (defined as 6+ months) than medium-
term (3-6 months) and relatively few studies reported on short-term treatment (up to 3 months). 
However, similar proportions of studies on long-term and shorter-term treatment reported relationships 
between mental health problems and retention. This was regardless of whether we looked at all studies 
together, or clusters of studies by type of mental health problem. Hence, there is no indication that 
differences in scheduled treatment duration are helpful in explaining inconsistencies between studies.      
 
Inpatient versus community-based treatments 
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Finally, we compared findings in different treatment settings. Again, similar patterns of results were 
observed for studies reporting on inpatient detoxification, residential rehabilitation, outpatient drug-free, 
day care, or substitution treatment. Clients with Axis-I disorders appeared to be as likely to be retained 
as those without mental health problems, independent of the treatment setting. Clients with personality 
disorders were less likely to be retained, and again type of service appeared to be unrelated to this. 
However, severity of symptoms may be more predictive of retention in inpatient settings, as studies in 
residential rehabilitation and detoxification services were particularly likely to report relationships 
between more severe mental health problems and dropout.  
 
DISCUSSION  
 
Despite the lack of a coherent effort to synthesise evidence, there appeared to be a wide-spread belief 
in the field that, as one author puts it, “early unplanned discharge is a feature of comorbidity” (Crawford 
2001). The aim of the current review was to see whether the available evidence supports this belief.  
 
Whilst there is considerable disparity in the results of the reviewed study, the tentative conclusion of this 
review is that most clients with a dual diagnosis who seek treatment in drug treatment services are 
retained as well as clients without dual diagnosis. Whilst overall dropout for clients is high in many 
studies, those with additional psychological problems do not seem at a disadvantage regarding their 
chance of staying in treatment long enough for it to have an impact. On the other hand, when examining 
the kinds of treatment programme offered in the participating services, it was interesting to note that 
only very few studies mention that psychiatric care was available to those with mental health problems. 
Whilst some authors may have omitted this information, it appears likely that this supports previous 
findings which suggests that specialist drug services tend to focus on treating the substance misuse 
problem rather than offering a comprehensive service to their dually diagnosed clients (Lewin et al. 
2004; Lowe and Abou-Saleh 2004). In light of this, we need to bear in mind that it is possible that in 
some cases longer retention is not necessarily positive: clients may stay in treatment longer because 
one of their key problems, ie mental health, is not adequately addressed and progress is hindered by 
this.  
 
Studies suggest that there may be a specific subgroup of clients who may be more vulnerable to 
premature dropout, namely those with anti-social personality disorder. It has been suggested that staff 
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may find it easier to empathise with, and therefore engage, clients with depression or anxiety disorders 
in contrast to those with anti-social personality disorder (Martinez-Raga et al. 2002), however, this 
assumption has not been investigated to date. Too few studies included clients with severe mental 
illness; hence, no conclusions can be drawn regarding this client group. 
 
There are a significant number of limitations that need to be considered when interpreting the findings 
of this review, both in terms of the quality of the evidence underlying this review and the review 
methodology itself.  
 
The client samples in the reviewed studies are unlikely to be representative of all those with dual 
diagnosis. The exclusion of clients with acute or severe mental illness was mentioned as a study 
exclusion criterion in many papers, and where this was the case, we have noted this in the “sample” 
column of the tables. However, we have to bear in mind that preselection is often at work even before 
studies start, as many drug services do not accept dual diagnosis clients with acute or severe mental 
health problems. In the UK, two recent surveys found that just 74% of all drug services and 55% of 
residential drug services accept dual diagnosis clients, and not all of them accepted acute cases (Meier 
and Best 2006; Schulte 2007). It is quite possible that in some of the other studies, researchers were 
unaware or did not report that clients with SMI were underrepresented in their samples.  
 
One key problem we faced when reviewing the available evidence was that it was often impossible to 
disentangle “true differences” between studies’ findings and differences caused by the inconsistent 
definitions and methodological approaches. Our ability to synthesise the available evidence and to 
determine whether treatment settings, interventions and patient characteristics explain differences 
between single and dual diagnosis clients was limited by 1) a lack of agreed upon definitions of both 
attrition and mental health problem, and 2) the consequent variation in assessment strategies.  
 
Attrition is often arbitrarily dichotomized into completion and non-completion and in most studies, no 
distinction was made between those who were asked to leave by the programme and those who 
decided to leave themselves. Other studies assess length of stay in treatment, or length of stay up to a 
study-end point chosen by the researchers. In many cases, the completion status was defined by the 
programme, and it is not clear whether clients would define the end of treatment in the same way.  
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There was also large variability regarding the measurement of mental health problems between studies. 
Apart from a multitude of different assessment instruments, we also found that studies reported either 
the presence of absence of a diagnosis or the overall severity of psychological symptoms but seldom 
both. Hence, we could extract little information on how different levels of severity of the same disorder 
might affect retention. 
 
Whilst most studies assessed mental health before or during treatment intake, some waited several 
weeks to allow substance-related symptoms to abate, and others did not specify when assessments 
were undertaken. Too few studies use the same assessment point to enable us to assess the effect of 
this. Whilst some studies adopted a multi-measure multiple-assessment points approach, most 
researchers report a single assessment for mental health problems. One-off assessments of dual 
diagnosis, especially at intake and during withdrawal can be unreliable as clients often seek help in mid-
crisis and withdrawal is an exceptional emotional situation. Problems with the reliability of diagnostic 
criteria for mental health disorders in current substance abusers have been previously documented 
(Gerstley et al. 1990; Bryant et al. 1992; Carroll et al. 1993). Many of the antisocial behaviours and 
borderline symptoms described in the DSM criteria for anti-social personality disorder (i.e. poor work 
performance and/or unemployment, criminality, irritability and impulsivity) are common correlates of 
substance abuse. Mood, anxiety and psychotic symptoms in drug users are not always stable or 
indicators of psychopathology, and reliable diagnoses of mental health problems in substance users are 
achieved only when assessments take into account the temporal patterns of the disorders (Hasin et al. 
2006). This was not commonly the case in the reviewed studies.  
 
There was often too little information about the treatment programme provided to enable true 
comparisons, especially regarding whether services offered targeted mental health interventions. 
Generally, there was also little control over other intervening variables and too few studies have 
included treatment process variables or early symptom improvement, which may moderate the dual-
diagnosis-retention relationship.  
 
Studies looking at symptom severity and length of time to dropout had an underlying assumption of 
linearity of the relationship However, as Epstein et al (1994) point out, this might not be justified. In a 
hypothetical example, those with few problems might start feeling better and consequently stay, those 
 14
with the most severe problems may be desperate and therefore stay, but those with moderate problems 
might see unsatisfactory initial improvement and leave. 
 
As noted previously, the evidence base is strongly biased towards US research, where funding, time-
limited approach to treatment, and philosophy of treatment provision are different from other countries. 
However, as far as it is possible to tell from a limited sample of non-US studies, US and non-US 
findings are broadly consistent. 
 
As in all reviews, there is the potential problem of publication bias (the “bottom-drawer” problem), and it 
is also common that authors select only a subset of the original variables to report in publications 
(Williamson and Gamble 2005). However, as non-publication of findings is more likely when there is no 
effect to report, we suggest that both biases are likely to shift the evidence further in the direction of our 
tentative main conclusion that there is no difference between dual diagnosis and single-diagnosis 
clients’ retention in drug treatment.  
 
Further limitations of this review are that research was not systematically scored according to 
methodological quality and that a meta-analytic approach could not be taken. Regarding the former, 
only few studies would have been included in a more formal systematic review with strict inclusion 
criteria, as the vast majority of studies used a cohort design with only limited attempts to control for 
intervening variables and changes over time. Meta-analysis was made impossible by the clinically and 
methodologically heterogeneous nature of the studies.  
 
Finally, this review of retention outcomes of dual diagnosis clients in drug treatment does not extend to 
other outcomes, and we cannot say whether dually diagnosed clients benefit from treatment to the 
same degree as single-diagnosis clients in terms of during and post-treatment drug use and 
psychosocial wellbeing. 
 
Further research directions 
 
There is an urgent need for studies in countries other than the US, as results cannot be generalised to 
countries with different treatment systems with any confidence. Clearly, larger-scale studies are needed 
that include all diagnostic groups and different treatment settings and use a sufficiently rigorous 
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methodology. There are several recommendations for the design of such studies, which would serve to 
surmount some of the difficulties encountered when assessing the evidence for this review. 1) Studies 
need to assess, report and, where appropriate, statistically control for intervening variables including at 
the very least symptom improvements, changes in substance use, and treatment delivery variables 
including any mental health treatment received by the clients. 2) Studies should use multiple well-
validated assessments of mental health, which include both diagnostic categories and severity 
assessments. Assessments should be scheduled to start at treatment intake and continue at regular 
intervals so that the co-variation of psychological symptoms with changes in substance use can be 
better understood. 3) Some studies should specifically include those with multiple co-morbidities, as 
currently little is known about possible cumulative effects of mental health problems. 4) Studies need to 
define clearly the indicators of retention, ideally including the length of stay in days as well as 
completion status. Regarding the latter, special attention should also be paid to the distinction between 
voluntary dropout and being asked to leave by the service, something that has been largely ignored in 
the past but that could potentially be relevant in the context of co-morbidity.  
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Tables 
 
 
Table 1. List of search terms 
1. Retention in treatment search string: 
(Retention or completion or attrition or dropout or premature discharge or days in treatment or weeks in 
treatment or months in treatment or length of stay) and (treatment or programme or program or 
intervention or rehabilitation) 
 
2. Dual diagnosis strings  
mental (health or disorder or illness) and substance (user or misuse or abuse or dependency or 
dependence or dependent or addicted or addiction)  
mental (health or disorder or illness) and drug (user or misuse or abuse or dependency or dependence 
or dependent or addicted or addiction) 
mental (health or disorder or illness) and (heroin or methadone or opiate or opioid or cocaine or crack or 
stimulant or alcohol) and (user or misuse or abuse or dependency or dependence or dependent or 
addicted or addiction) 
(dual diagnosis or dually diagnosed or co-morbidity or comorbidity or co-morbid or comorbid) 
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Table 2. Relationship between psychiatric problems and retention in drug treatment: Axis-I disorders 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea Type of 
service 
Tx 
durati
on 
Axis-I disorders (non-psychotic) 
Alterman et al 
1996 
No effect of DEPR Control: 83%; 
DEPR only: 75%; 
APD only and 
APD+DEPR: 
71%  
SCID, PDE Completion 
of 7 mo, 
days in 
treatment 
APD (13%), Depr 
(33%), Depr & APD 
(19%), Drugs only 
(35%) 
184 male opiate 
users, SMI 
excluded , Axis-I 
excl if not also 
Depr 
MM + 
infrequent 
counselling 
>6mo 
Araujo et al  
1996 
No effect of DEPR or 
ANX 
65.5% overall HAM-D, HAM-
A 
Completion 
of detox (5-
10 days) 
n/a 148 heroin and 
cocaine users 
i/p detox <2 
wks 
Avants et al  
1999 
No effect for DEPR 81% complete 
12-wk 
programme 
SCID  Length of 
stay 
22% current APD, 25% 
major DEPR 
291 opiate users  O/p 
enhanced 
MM 
3mo 
Avants et al  
2000 
No effect of DEPR 12-wk retention: 
73% (DEPR), 
78% (non-DEPR) 
SCID, BDI  Length of 
stay 
Depression 
(49% above BDI cut-off) 
307 opiate users  O/p 
enhanced 
MM 
3mo 
Broome et al 
1999  
Interaction with 
modality: RR: Current 
DEPR predicts 
completion. No effect 
for ANX. MM and 
ODF: no effects 
n/a SCL-90 DEPR, 
DIS ANX & 
DEPR 
Completion 
of 90 days 
(o/p, RR) or 
360 days 
(MM) 
n/a 2,362 in LTR, 
1,896 in ODF, 
1,011 in MM 
RR, o/p MM, 
ODF, some 
with psychol 
services 
>6mo 
Charney et al 
1998 
No effect of DEPR 66% at 3 mo HAM-D, 
GAF, BDI 
Completion 
of 3 mo 
36% DEPR (19% ANX, 
35% PDs, 5% 
psychosis) 
75 substance 
users 
ODF >6mo 
Curran et al 
2002 
Severe DEPR 
associated with early 
dropout but not late 
dropout. No effect for 
mild DEPR 
80% completion 
(of dropout 64% 
was classified as 
early)  
DEPR-
Arkansas (D-
ARK), BDI, 
own PTSD 
screening 
Early (<5 
sessions) 
and late 
dropout 
67% major DEPR 
disorder, 81% PTSD 
126 male 
substance users  
Intensive 
ODF 
<1mo 
Gerra et al 
2006 
Better retention for 
DEPR clients than 
other diagnoses or 
drug use only. Worse 
retention of ANX 
clients compared to 
drugs only (Depr > 
Drugs only >ANX > 
PD > SC) 
Total sample: 6 
mo: 54%, 12 mo: 
44%– 12-mo 
retention: drugs 
only 45%, DEPR 
72%, ANX  39%, 
PD 18%, SC 8%  
SCID and 
Structured 
Interview for 
DSM-IV for 
Axis II 
 
Completion 
of 12 mo 
30% 
DEPR, 11% ANX, 6% 
SC, 22% BPD/APD, 
32% drugs only 
206 opiate users  Buprenorphi
ne 
maintenance 
>6mo 
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Table 2. Relationship between psychiatric problems and retention in drug treatment: Axis-I disorders (cont.) 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea Intervention Tx 
durati
on 
Gonzalez et 
al  
2003 
No effect of DEPR  Lifetime 
DEPR: HAM-
D, 
CESDI, SCID 
Retention 36% with major DEPR, 
64% no DD 
149 cocaine & 
opiate users, SMI 
excl 
Several o/p 3mo 
Hiller et al 
1999 
No effect of DEPR or 
ANX in multivariate 
model. (Univariate: 
completers had lower 
DEPR and ANX)  
77% completion Psychiatric & 
treatment 
history, TCU 
DEPR and 
ANX scale 
Completion n/a 339 drug users  Prison and 
transition 
after prison - 
TC-based 
units 
>6mo 
Joe, Simpson 
& Broome 
1999 
RR only: DEPR 
modestly related to 
better retention. No 
effect in other 
modalities  
64% RR, 55% 
ODF, 54% MM 
DIS, CIDI, 
SCL-90 
Completion 
of 90 days 
(RR and 
ODC), 360 
days MM 
 3,209 drug users 
retained > 1 mo 
RR, MM o/p, 
ODF o/p 
>6mo 
King et al  
1999 
No effect for ADHD 
diagnosis 
12mo retention 
rate: 76%, 18% 
of ADHD, 25% of 
non-ADHD 
SCID, ADHD 
interview, CPT 
(also ADHD) 
Length of 
stay 
ADHD vs no ADHD 125 opiate users MM plus 
counselling 
(weekly or 
more) 
>6mo 
Kleinman et a 
1992 
DEPR related to 
dropout. 
70% stay > 2 
sessions, 30% 
stay > 8 sessions 
SCL-90, BDI Number of 
sessions 
attended 
 86 cocaine/crack 
users 
ODF 3-
6mo 
Knight et al  
2001 
No effect of DEPR or 
ANX 
44% completion TCU DEPR 
and ANX 
scales 
Completion 18% high DEPR scores, 
40% high ANX scores 
87 women 6-12-mo RR 
for women 
with children 
>6mo 
Kokkevi et al 
1998 
DEPR related to 
dropout, ANX to 
retention. 
Retention at 4-6 
weeks: 80% 
SCID-R, CIDI Completion 60% any PD (34% APD, 
28% BPD), Axis-I only 
20%, Axis-I & II 40% 
Axis II only 20%, Drugs 
only 21% 
226 drug users, 
SMI excl 
ODF and i/p 
drug-free 
3-
6mo 
Lang & 
Belenko 
2000 
No effect of DEPR. 
ANX related to 
dropout 
61% completion TCU DEPR 
and ANX 
scales 
Completion  150 drug users, 
offenders, SMI 
excl 
Long-term 
RR (TC) -
instead of 
prison 
>6mo 
Martinez-
Raga 
2002 
DEPR related to 
completion. No effect 
for ANX or PTSD 
67% planned 
discharge 
Diagnoses 
through 
psychiatrists 
Unplanned 
discharge 
36% DEPR, 23% ANX, 
8% PTSD, 17% BPD, 
20% APD 
482 alcohol 
users 
alcohol 
detox & 
relapse 
prevention  
1mo 
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Table 2. Relationship between psychiatric problems and retention in drug treatment: Axis-I disorders (cont.) 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea Intervention Tx 
durati
on 
Meier et al  
2006 
No effect of DEPR or 
ANX 
54% stay 3+ mo TCU DEPR 
and ANX 
scales 
Completion 
of 3 mo 
73% DEPR, 44% past 
suicide attempts  
187 drug users RR 3-
6mo 
Petry & Bickel 
1999 
No effect of DEPR 56% stay 4+ mo ASI, BDI Completion 
of 4 mo 
 114 opiate users, 
untreated SMI 
excl 
Buprenorphi
ne & 
counselling, 
o/p 
3-
6mo 
Ravndal & 
Vaglum  
1994 
No effect of DEPR 12mo retention: 
30% (30% 
DEPR, 29% non-
DEPR) 
MCMI 
Dysthymia, 
SCL-90 
Completion 
of 12mo 
69% DEPR 144 users RR (TC) 
followed by 
o/p aftercare 
>6mo 
Ryan et al 
1995 
No effect of DEPR 42% complete 8 
weeks 
BDI, ASI, 
clinician rating 
Completion 
of 8 weeks 
n/a 98 alcohol users O/p alcohol 1-
3mo 
Sayre et al 
2002 
No effect of DEPR 35% complete 20 
sessions 
BDI, ASI Completion 
of 20 
sessions, 
early vs late 
attrition 
 165 cocaine 
users, heroin 
excl, current 
Axis-I excl 
o/p cocaine  3mo 
Siqueland et 
al 
1998 
No effect of DEPR 51% completion  BSIGSI, BDI, 
HAM-D, SCID 
Length of 
stay (to 6 
month) 
Axis-I (25%), PD (48% 
with 19% APD) 
286 cocaine 
users (only 
considering 
those 
randomised to 
treatment), SMI 
excl 
ODF: DYN, 
CBT, IDC  
6mo 
Schizophrenia 
Gerra et al 
2006 
Retention rates were 
lowest for clients with 
SC compared to 
clients with DEPR, 
ANX, PD or drug use 
only 
Total sample: 6 
mo: 54%, 12 mo: 
44%– 12-mo 
retention: DEPR 
72%, drugs only 
45%, ANX 39%, 
PD 18%, SC 8%  
SCID and 
Structured 
Interview for 
DSM-IV for 
Axis II 
Completion 
of 12 mo 
30% 
DEPR, 11% ANX, 6% 
SC, 22% BPD/APD, 
32% drugs only 
206 opiate users  Buprenorphi
ne 
maintenance 
>6mo 
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Table 2. Relationship between psychiatric problems and retention in drug treatment: Axis-I disorders (cont.) 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea Intervention Tx 
durati
on 
Axis-I disorders (all) 
Cacciola et al 
2001 
No effect for Axis I 
diagnoses 
Retention rates:  
Axis I & II: 65%,  
Axis II: 67%, 
drugs only: 82%, 
Axis I: 83% 
SCID, SIDP-R Dropout 
before 
month 7 
Drugs only, Axis I, Axis 
II, Axis I & II 
278 opiate users, 
only 45 women, 
SMI excl  
MM >6mo 
Moos & King 
1997 
Axis-I diagnosis 
related to dropout 
55% completion BSI Completion 33% Axis-I diagnosis 2794 substance 
users (99% 
male) 
RR 1-
3mo 
Nuttbrock et 
al 
1998 
No effect for Axis-I 
diagnosis 
2mo retention: 
79%, 6mo 
retention 48%, 
12mo retention 
30% 
CES-D, BPRS, 
GAF  
Completion 
of 6 mo and 
12 mo 
49% psychosis, 22% 
DEPR 
290 DD clients   RR: TC 
(n=169) and 
community 
residence 
(n=121) 
>6mo 
Saxon & 
Calsyn 
1995 
Axis-I disorder related 
to better retention. 
6-mo completion 
70% of Axis-I 
clients, 59% 
drugs only clients 
Psychiatrist 
diagnosis 
Length of 
stay 
Axis- I (46.4%) vs drugs 
only (53.6%) 
222 drug users O/p (3 
groups: 
MM/Naltrexo
ne/ODF), 
DD routine 
psychiatric 
care 
>6mo 
Siqueland et 
al 
1998 
No effect for Axis-I 
diagnosis (marginally 
longer retention; 
p<.09).  
51% completion  BSIGSI, BDI, 
HAM-D, SCID 
Length of 
treatment (to 
6 month) 
Axis-I (25%), PD (48% 
with 19% APD) 
286 cocaine 
users (only 
considering 
clients 
randomised to 
treatment), SMI 
excl 
ODF: DYN, 
CBT, IDC  
6mo 
Key: Treatment forms: o/p=outpatient, i/p=inpatient, RR=residential rehabilitation, DC=day care, TC=therapeutic community, MM=methadone maintenance, ODF- outpatient drug-
free treatment; IDC=drug counselling, DYN=dynamic psychotherapy, CBT= cognitive/cognitive behaviour therapy, o/c=outcome, MH Mental Health, DD=Dual Diagnosis, Intensive = 
3+ visits per week in o/p treatment. Enhanced = offering components in addition to MM or Counselling, Mental Health: DEPR = depression, ANX=anxiety, PD= Personality Disorder, 
APD = Antisocial Personality Disorder, BPD = Borderline Personality Disorder, PTSD = post traumatic stress disorder, SC=Schizophrenia, SMI – severe mental illness  
a where exclusion of SMI clients was not mentioned by authors, it was assumed that SMI clients are included.  
b Study focus denotes whether the investigators had specifically designed their study to inform on the link between psychiatric problems and retention 
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Table 3. Relationship between psychiatric problems and retention in drug treatment: Axis-II disorders 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea  Intervention Tx 
durati
on 
AXIS-II/Personality disorders 
Alterman et al 
1996 
No effect for APD  7-mo retention: 
drugs only: 83%; 
DEPR only: 75%; 
APD only and 
APD+DEPR: 
71% 
SCID, PDE Completion 
of 7 mo, 
days in 
treatment 
 
APD (13%), Depr 
(33%), Depr & APD 
(19%), Drugs only 
(35%) 
184 opiate users, 
SMI excl 
MM + 
counselling 
(weekly or 
less) 
>6mo 
Avants et al 
1999 
APD related to 
dropout. 
81% complete 
12-wk 
programme 
SCID  Length of 
stay 
22% current APD,  
25% major DEPR 
291 opiate users O/p 
enhanced 
MM 
3mo 
Cacciola et al 
2001 
PDs related to 
dropout (whether or 
not with Axis I 
disorder).  
Retention rates: 
Axis I & II: 65%,  
Axis II: 67%, 
drugs only: 82%, 
Axis I: 83% 
SCID, SIDP-R Dropout 
before 
month 7 
Drugs only,  
Axis I,  
Axis II, 
Axis I & II 
278 opiate users, 
MSI excluded 
O/p MM >6mo 
Darke et al 
2005 
No effect for BPD. 12-mo retention 
BPD 42%, non 
BPD 39% (ns), 
days in tx: BPD 
164, non-BPD 
182 (ns), no 
difference by 
modality 
CIDI 
BPD  
Completion, 
Days in 
treatment 
45% BPD (by modality: 
MM 34%, detox 46%, 
RR 60%, No tx 43%:) 
 
485 substance 
users 
MM, detox, 
RR 
>6mo 
Gerra et al 
2006 
PDs related to 
dropout: Clients with 
PD worse retention 
than clients with drug 
use only or DEPR or 
ANX, but higher than 
for clients with SC.  
Total sample: 6 
mo: 54%, 12 mo: 
44%– 12-mo 
retention: drugs 
only 45%, DEPR 
72%, ANX 39%, 
PD 18%, SC 8%  
SCID and 
Structured 
Interview for 
DSM-IV for 
Axis II 
Completion 
of 12 mo 
30% DEPR, 11% ANX, 
6% SC, 22% BPD/APD, 
32% drugs only 
206 opiate users 
(68% with co-
morbidity) 
Buprenorphi
ne 
maintenance 
>6mo 
Gill et al 
1992 
No effect for APD. 12-mo retention: 
20%  
DIS-III 
 
Days in 
treatment 
42% APD, 58% drugs 
only 
55 opiate users  MM >6mo 
Goldstein et 
al  
1999 
APD clients higher 
dropout rate only in 
6mo, not in 3mo 
treatment (marginal)  
Not given DIS-III-R Length of 
stay 
APD diagnosis vs 
antisocial behaviour 
without diagnosis 
257 drug users, 
SMI excl 
RR Trial: 
3mo 
vs 
6mo 
trial  
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Table 3. Relationship between psychiatric problems and retention in drug treatment: Axis-II disorders (cont.) 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea  Intervention Tx 
durati
on 
Haller et al 
1997 
APD related to 
retention. 
39% complete 
20-wk 
programme 
SCID, SIDP-R Days in 
treatment & 
completion 
APD (31%) 65 perinatal 
female drug/alc 
users 
3-day/wk 
day care, 
Psychothera
py 
3-
6mo 
King et al  
2001 
No effect for APD 12mo retention: 
Drugs only: 40%,  
APD only 38%, 
other psychiatric 
only 40%, APD + 
other 47%  
SCID, ADHD 
interview 
based on 
DSM-IV 
Length of 
stay 
APD only (14%),  
APD & other psychiatric 
(10%),  
other psychiatric only 
(25%),  
drugs only (51%) 
513 opiate users MM plus 
counselling 
(weekly or 
more) 
>6mo 
Kokkevi et al 
1998 
No effect for any PDs Retention at 4-6 
weeks: 80% 
SCID-R, CIDI Completion 60% any PD (34% APD, 
28% BPD) 
Axis-I only 20% 
Axis-I & II 40% 
Axis II only 20% 
Drugs only 21% 
226 drug users, 
SMI excl 
O/p and i/p 3-
6mo 
Marlowe et al 
1997 
No effect for number 
of PD-related 
symptoms nor 
diagnoses  
n/a  SCID-II, BDI, 
BAI 
Length of 
stay 
75% any PD (26% APD, 
20% BPD, 17% 
narcissistic, 22% 
paranoid) 
137 cocaine 
users 
ODF CBT-
based 
individual 
and/or group 
therapy with 
contingency 
managemen
t 
1-
3mo 
Martinez-
Raga  
2002 
APD and BPD 
associated with 
dropout 
67% planned 
discharge 
Diagnoses 
through 
psychiatrists 
Unplanned 
discharge 
36% DEPR, 23% ANX, 
8% PTSD, 17% BPD, 
20% APD 
482 alcohol 
users 
Alcohol 
detox & 
relapse 
prevention 
1mo 
Siqueland et 
al 
1998 
APD related to 
dropout (p<.06), no 
effect for other PDs 
51% completion  BSIGSI, BDI, 
HAM-D, SCID 
Length of 
treatment (to 
6 month) 
Axis-I (25%), PD (48% 
with 19% APD) 
286 cocaine 
users (only those 
randomised to 
treatment), SMI 
excl 
ODF: DYN, 
CBT, IDC  
6mo 
Key: Treatment types: o/p=outpatient, i/p=inpatient, RR=residential rehabilitation, DC=day care, TC=therapeutic community, MM=methadone maintenance, ODF- outpatient drug-
free treatment; IDC=drug counselling, DYN=dynamic psychotherapy, CBT= cognitive/cognitive behaviour therapy, o/c=outcome, MH Mental Health, DD=Dual Diagnosis, Intensive = 
3+ visits per week in o/p treatment. Enhanced = offering components in addition to MM or Counselling, Mental Health: DEPR = depression, ANX=anxiety, PD= Personality Disorder, 
APD = Antisocial Personality Disorder, BPD = Borderline Personality Disorder, PTSD = post traumatic stress disorder, SC=Schizophrenia, SMI – severe mental illness  
a where exclusion of SMI clients was not mentioned by authors, it was assumed that SMI clients are included.  
b Study focus denotes whether the investigators had specifically designed their study to inform on the link between psychiatric problems and retention 
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Table 4. Relationship between psychiatric problems and retention: The role of psychiatric treatment history and global severity scales 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea  Intervention Tx 
durati
on 
Psychiatric severity scales 
Carroll et al  
1993 
High ASI-P score 
related to dropout 
n/a ASI Psych, 
Schedule for 
Affective 
Disorders and 
Schizophrenia  
Length of 
stay 
53% had current 
diagnosis, 46% 
affective, 14% ANX 
298 cocaine 
users, heroin 
users excl 
O/p drug 
free and i/p 
3-
6mo 
Epstein et al 
1994 
No effect for SCL-90 
score  
14% baseline, 
21% dropout, 
22% part 
completion, 43% 
completion 
SCL-90-R Dropout 
(session 0-
4), part 
completion 
(5-14), 
completion 
(15+) 
N/a 105 male alcohol 
users, SMI excl  
o/p couple 
therapy 
3-
6mo 
Green et al  
2002 
ASI-P related to 
dropout for men, but 
not women. No effect 
for number of MH 
complaints 
43% completion ASI Completion N/a 293 substance 
users 
ODF 1-
3mo 
Haller, Miles 
& Dawson  
2002 (?same 
parent study 
as 2004) 
Severity of 
psychopathology 
related to dropout  
Mild, moderate 
and severe 
psychopathology 
competion rates 
were 36%, 57%, 
76%. 
MCMI-III 
psychopathol
ogy 
Completion N/a 78 women drug 
users 
DC 3-
6mo  
Haller & Miles 
2004 
Severity of 
psychopathology 
related to dropout 
Mild, moderate 
and severe 
psychopathology 
completion rates 
were 66%, 45%, 
29%. 
MCMI-III 
psychopathol
ogy 
Completion N/a 97 women drug 
users 
RR 3-
6mo 
Kissin et al  
2004 
ASI-P related to 
dropout 
81% completion ASI Length of 
stay, 
completion 
N/a 152 pregnant 
women  
7-day 
residential 
stay 
<2wk
s 
Lang & 
Belenko  
2000 
ASI-P related to 
dropout 
61% completion ASI Completion  150 drug users, 
offenders, SMI 
excl 
Long-term 
RR (TC) -
instead of 
prison 
>6mo 
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Table 4. Relationship between psychiatric problems and retention: The role of psychiatric treatment history and global severity scales (cont.) 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea  Intervention Tx 
durati
on 
McCaul et al 
2001 
No effect for ASI-P 
score 
% not given, LOS 
means between 
105 and 163 
days depending 
on drug group 
ASI Length of 
stay 
N/a  268 alcohol, drug 
and drug & 
alcohol users 
Intensive 
ODF 
>6mo 
Mertens & 
Weisner  
2000 
ASI-P related to 
shorter stay for 
women, not men 
(weak effect). No 
difference in 
completion rate. 
55% stay >1mo, 
25% >2mo 
ASI Length of 
stay, 
completion 
N/a 317 women and 
599 men 
Several 
alcohol and 
drug o/p 
1-
3mo 
Petry & Bickel 
1999 
ASI-P related to 
dropout (moderated 
by alliance)  
56% stay 4mo ASI, BDI Completion 
of 4 mo in 
treatment 
N/a 114 opiate users, 
untreated SMI 
excl 
Buprenorphi
ne & 
counselling, 
o/p 
3-
6mo 
 
Ryan et al   
1995 
No effect for ASI-P 
score 
42% complete 8 
weeks 
BDI, ASI, 
clinician rating 
Completion 
of 8 weeks 
N/a 98 alcohol users O/p alcohol 
treatment  
1-
3mo
Saxon et al  
1996 
No effect for ASI-P 
score 
18-mo retention: 
22% 
ASI Completion N/a 353 opiate 
users 
MM >6mo 
Sayre et al  
2002 
No effect for ASI-P 
score 
35% complete BDI, ASI Completion 
of 20 
sessions, 
early vs late 
attrition 
N/a 165 cocaine 
users, current 
Axis-I excl 
o/p cocaine  3mo 
Siqueland et 
al 
2002 
Psych problems 
related to shorter stay 
for women, longer 
stay for men  
31% complete 6 
mo 
Composite 
score made up 
of BSIGSI, 
HAM-D, BDI, 
SCID 
Length of 
stay 
14% full APD, 32% APD 
without childhood onset, 
28% cocaine-induced 
mood disorder, 5% 
cocaine-induced ANX 
disorder 
487 cocaine 
users, DD 
requiring 
medication excl 
O/p DYN, 
CBT, IDC 
6mo 
Tidey et al  
1998 
No effect for ASI-P 
score 
n/a ASI Length of 
stay 
Severity: 23% low, 38% 
medium, 39% high  
185 drug users O/p 
counselling 
6mo 
Van Stelle et 
al  
2004 
Severity of 
psychopathy and 
psychiatric symptoms 
related to dropout. 
25% completion 
rate 
BSI, PCL-SV, 
DPRS, PSAS, 
ASI 
Completion 
of 9-month 
programme 
100% 179 DD men 
(mainly alcohol & 
cocaine) 
DD unit, jail-
based RR 
(TC)  
>6mo 
Wallace & 
Weeks 
 2004 
No effect for ASI-P 
score 
71% retention 
rate 
ASI Length of 
stay, 
Completion 
N/a 133 mainly 
alcohol users 
Intensive 
ODF  
1-
3mo 
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Table 4. Relationship between psychiatric problems and retention: The role of psychiatric treatment history and global severity scales (cont.) 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea  Intervention Tx 
durati
on 
Psychiatric history/past problems 
Agosti et al  
1996 
No effect of past 
DEPR 
4-wk retention: 
31%  
(clinic’s own) 
Life History 
Questionnaire 
Completion 
of 1 mo 
History of treatment for 
Depr 
198 cocaine 
users 
ODF 1-
3mo 
Brady et al 
2004 
No effect for past MH 
treatment, but clients 
with MH history were 
3x as likely to be 
asked to leave 
Variation by 
programme from 
10% to 68% 
completion 
Self-report 
history of 
mental health 
treatment 
Completion 
vs dropout 
vs asked to 
leave vs 
leave prison 
before 
completion 
9.1% MH treatment 
history 
690 prisoners 5 prison 
programmes
: 3 TCs, 2 
eclectic with 
12-step 
component, 
1 education, 
standard MH 
services 
1-3 
and 
3-
6mo 
Broome et al 
1999  
Interaction with 
modality: RR/ODF: no 
effect. MM: lifetime 
ANX/DEPR diagnosis 
predicts dropout. 
n/a SCL-90 DEPR, 
DIS ANX & 
DEPR 
Completion 
of 90 days 
(o/p, RR) or 
360 days 
(MM) 
 2,362 in LTR, 
1,896 in ODF, 
1,011 in MM 
RR, o/p MM, 
ODF, some 
with psychol 
services 
>6mo 
Claus & 
Kindleberger 
2002 
No effect for past MH 
treatment 
60% retained for 
>2 sessions 
Previous MH 
treatment, DD 
according to 
ISAP (Hile et al 
1998) 
Dropout 
after 1-2 
sessions vs 
stay for 3+ 
sessions 
 260 drug, alcohol 
and both drug 
and alcohol 
Centralised 
assessment 
and referral 
to RR or 
ODF 
1-
3mo 
Hiller et al 
1999 
No effect for past MH 
treatment 
77% completion Treatment 7 
MH history, 
TCU DEPR, 
ANX scale 
Completion n/a 339 drug users Prison - TC-
based unit 
>6mo 
Lang & 
Belenko  
2000 
History of MH 
treatment related to 
dropout 
61% completion Previous MH 
treatment 
Completion  150 drug users, 
offenders, SMI 
excl 
Long-term 
RR (TC) -
instead of 
prison 
>6mo 
Laudet et al 
2003 
More prior MH 
treatment related to 
completion. Current 
psychiatric 
medication related to 
dropout. 
12-month 
retention 71% 
Previous MH 
treatment, 
Colorado 
Symptoms 
Index 
Completion 
of 1 yr 
For completers/non-
completers: SC 
(39%/27%), Depr 
(22%/28%), Bipolar 
(24%/24%). MH 
treatment (92%/83%), 
on MH medication 
(91%/98%) 
276 drug users, 
retained for 1+ 
month 
12-step 
groups, DD-
provision 
>6mo 
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Table 4. Relationship between psychiatric problems and retention: The role of psychiatric treatment history and global severity scales (cont.) 
Authors Effect Retention rate Mental Health 
measure 
Retention 
Measure 
Diagnostic groups/ 
Prevalence of DD in 
sample 
Samplea  Intervention Tx 
durati
on 
Other psychiatric indicators      
Claus & 
Kindleberger 
2002 
No difference in very 
early dropout 
according DD  
60% retained for 
>2 sessions 
DD according 
to ISAP (Hile 
et al 1998) 
Dropout 
after 1-2 vs 
stay for 3+ 
sessions 
N/a 260 drug, alcohol 
and both drug 
and alcohol 
Centralised 
assessment 
& referral to 
RR or ODF 
1-
3mo 
King et al 
2001 
No effect for 
psychiatric diagnoses 
other than APD 
12mo retention 
rate: Drugs only: 
40%,  APD only 
38%, other 
psychiatric only 
40%, APD + 
other 47%  
SCID, ADHD 
interview 
based on 
DSM-IV  
Length of 
stay 
APD only (14%),  
APD & other psychiatric 
(10%),  
other psychiatric only 
(25%),  
drugs only (51%) 
513 opiate users MM plus 
counselling 
(weekly or 
more) 
>6 mo 
 
Magura et al  
1998 
No effect of presence 
of any MH problems 
3yr retention 
38% 
Client notes – 
MH problem 
yes/no 
Length of 
stay 
25% had MH problems 1026 opiate 
users 
MM >6mo 
Pani et al  
1997 
No effect of presence 
of DD 
56% for DD, 
63.3% for non-
DD at 1 yr (ns) 
Psychiatrist’s 
diagnosis 
Length of 
stay for 2 yrs 
19% (severe) DD  124 drug users 
(subsample with 
retention data) 
MM >6mo 
         
Dual Diagnosis Specialist Units 
Ball et al  
2005 
PDs severity related 
to dropout in trial 
treatment only.  
40% stay >1mo SCID, PDQ-
4R, ASI, BSI 
Length of 
stay 
100% PD  (no 
subgroups) 
52 homeless 
substance 
abusers, acute 
SMI excl 
DD 
specialist: 
RCT of new 
counselling 
method for 
PD 
6mo 
Galanter et al 
1996 
No effect of DEPR. 
No effect for SC  
N/a Psychiatrist 
evaluation, 
ASI, prior 
hospitalisation 
Months in 
treatment 
24% SC, 17% major 
DEPR, 59% all other 
(incl drugs only and 
Axis-II) 
 
298 cocaine 
users 
Drug-free 
day care, 
psychiatric 
managemen
t  
>6mo 
Greenberg et 
al  
1994 
APD strongly related 
to dropout, no effect 
for other PD. No 
effect of Axis I 
diagnosis (among 
clients with PD) 
62% completion Psychiatrist 
discharge form 
Completion 
of 6 week 
programme 
100% DD.  PD with or 
without Axis-I (44.6%), 
or Axis-I only (55.4%) 
316 DD clients 
(mainly alcohol 
and cocaine) 
DD 
specialist i/p 
unit 
<3mo 
Maremmani 
et al 
No effect for Axis-I 
diagnosis 
DD: 87% stay > 
3 mo, 50% > 1yr, 
Psychiatrist 
diagnoses 
Completion 
of 90 days 
Axis I- DD vs no DD 90 opiate users  DD 
specialist 
>6mo 
 30
2000 no-DD 85% stay 
>3 mo, 42% > 
1yr   
(Axis-I only) O/p MM 
Mierlak et al 
1998 
More MH inpatient 
admissions related to 
dropout 
6mo retention 
34% 
MH treatment 
history 
Completion 
of 6 mo 
100% Axis-I (66% 
psychosis, 33 affective) 
189 DD 
homeless men 
with SMI 
Modified TC 
(RR) for DD 
6mo 
Ross et al 
1997 
No effect for SCL-90 
score 
72% completion SCL-90-R Completion N/a 282 drug users, 
SMI referred on 
Specialist 
DD, Several 
o/p (2 week 
DC or 8 
sessions 1-
2-1 
counselling) 
<1mo 
Key: Treatment forms: o/p=outpatient, i/p=inpatient, RR=residential rehabilitation, DC=day care, TC=therapeutic community, MM=methadone maintenance, ODF- outpatient drug-
free treatment; IDC=drug counselling, DYN=dynamic psychotherapy, CBT= cognitive/cognitive behaviour therapy, o/c=outcome, MH Mental Health, DD=Dual Diagnosis, Intensive = 
3+ visits per week in o/p treatment. Enhanced = offering components in addition to MM or Counselling, Mental Health: DEPR = depression, ANX=anxiety, PD= Personality Disorder, 
APD = Antisocial Personality Disorder, BPD = Borderline Personality Disorder, PTSD = post traumatic stress disorder, SC=Schizophrenia, SMI – severe mental illness  
a where exclusion of SMI clients was not mentioned by authors, it was assumed that SMI clients are included.  
b Study focus denotes whether the investigators had specifically designed their study to inform on the link between psychiatric problems and retention 
 
 
 
 
